NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

GUIDE-HF STUDY DATA SHOW ABBOTT’S CARDIOMEMS™ DEVICE CAN IMPROVE CARE FOR MORE PATIENTS WITH HEART FAILURE

by Ed Johnson
August 28, 2021
A A

– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device

– Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease

Abbott (NYSE: ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV heart failure. Data adjusted for the impact of COVID-19 show a strong reduction in a composite endpoint of heart failure hospitalizations, emergency visits and death in a broad range of patients, suggesting new benefits from the CardioMEMS device.

CardioMEMS is currently approved for use in NYHA Class III patients with a prior heart failure hospitalization within the last year. The GUIDE-HF study examined an expanded patient population, including patients with NYHA Class II and Class IV heart failure, to evaluate the device in patients in earlier or later-stage disease progression.

GUIDE-HF is one of many large trials conducted amid the COVID-19 pandemic, when healthcare systems experienced significant disruption. Heart failure patients are at a heightened risk of COVID-19 and – as a result – experienced changes to their care management and hospitalization during the pandemic. An analysis of the full one-year data set, of which 28% of the follow-up data was collected during COVID-19, showed CardioMEMS-guided patients had a lower composite endpoint rate of total heart failure events and death compared to the study’s control group, which was not statistically significant. In an analysis of data adjusted for the impact of COVID-19 (captured prior to March 13, 2020 – the date the U.S. national emergency was declared), CardioMEMS demonstrated a significant 19% reduction in the study’s composite endpoint and a 28% reduction in heart failure hospitalizations.

The results of GUIDE-HF were presented at the ESC Congress 2021 (organized by the European Society of Cardiology) and simultaneously published in The Lancet. Based on the strength of the GUIDE-HF data, Abbott has filed a Premarket Approval (PMA) supplement with the U.S. Food and Drug Administration (FDA) for consideration of an expanded indication for the CardioMEMS device.

The CardioMEMS HF System includes a small sensor the size of a paperclip that, once placed in the pulmonary artery during a minimally invasive procedure, monitors for pressure changes that indicate worsening heart failure even before patients feel symptoms. The CardioMEMS sensor connects to a system that remotely provides daily pressure readings to a patient’s clinical team, allowing physicians to make therapy changes to combat worsening heart failure.

“The two most important strategies in treating heart failure are helping doctors stay ahead of the condition as it progresses and keeping people stable and out of the hospital and emergency room. The GUIDE-HF trial shows that Abbott’s CardioMEMS device has a role in both,” said Philip B. Adamson, M.D., chief medical officer of Abbott’s heart failure business. “This tiny cardiac sensor, coupled with the increased improvements in informed telemedicine, can have a tremendous impact on helping people at all stages of heart failure live their healthiest lives.”

GUIDE-HF Data Overview
Though not designed to assess the benefits of CardioMEMS in specific patient sub-groups, when adjusted for the impact of COVID-19, the GUIDE-HF study suggests potential benefits of the device in new groups of patients, including: 

  • Patients in earlier stages of heart disease. GUIDE-HF data suggests better outcomes in Class II patients when their therapy is guided by pulmonary pressure monitoring, with a 34% reduction in heart failure hospitalizations, emergency visits and death.
  • Specific patient groups. GUIDE-HF also demonstrated a relative risk reduction for both women (33%) and African American patients (41%), two patient segments disproportionately impacted by effects of heart failure.
  • Patients at risk of potential hospitalization. GUIDE-HF showed a 25% reduction in hospitalization or emergency department visits in patients without a prior heart failure hospitalization but who undergo blood tests that show elevated levels of a biomarker known as B-type Natriuretic Peptide (BNP), which indicates worsening heart failure.

“Clinicians have seen firsthand the importance of CardioMEMS in helping them proactively manage heart failure to keep patients out of the hospital, and the GUIDE-HF trial showed the device provides benefits for more patients than ever before,” said JoAnn Lindenfeld, M.D., primary investigator for the GUIDE-HF trial and director of advanced heart failure at Vanderbilt University Medical Center in Nashville, Tenn. “Even with the disruptions that we saw as a result of the COVID-19 pandemic, this trial was still able to show significant reductions in heart failure hospitalizations and reduced emergency visits with pulmonary pressure sensor monitoring.”

Tags: < Corporate Events
ShareTweetShareSend

Related Industries

Healthcare

Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.

September 20, 2023
Healthcare

BD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards

September 20, 2023
Healthcare

Celanese Announces Agreement with the Population Council for Sustained Release Dual-API Therapeutic

September 13, 2023
Healthcare

Thermo Fisher Scientific and National Minority Quality Forum Collaborate to Make Clinical Research More Accessible to Historically Underserved Communities

September 8, 2023
Healthcare

Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes

September 6, 2023
Healthcare

AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

September 2, 2023
In confidential computing, data remains encrypted for as long as possible and until it is inside a secure enclave where it can be decrypted for processing. Encrypted computing takes confidential computing to a new level by using a technique called fully homomorphic encryption, which allows the hardware to process the data without it ever being decrypted. In essence, the processor performs calculations directly on the encrypted data. (Credit: Intel Corporation)

Intel Innovation 2023: Accelerating the Convergence of AI and Security

September 21, 2023

...

Steamship Authority Electrifies Fleet with BYD – RIDE Zero-Emission Buses

September 26, 2023

...

SABIC AN in collaborative venture with US companies to support Sustainable Agriculture

September 4, 2023

...

IBM Brings New Capabilities to its Sustainability Software to Help Organizations Accurately and Efficiently Operationalize Scope 3 Greenhouse Gas Emissions Insights

September 21, 2023

...

Mastercard SpendingPulse: U.S. Retail Sales Expected to Grow 3.7%* This Holiday Season

September 20, 2023

...

Carrier Named a TIME World’s Best Company

September 13, 2023

...

Carlyle Joins GTCR As Strategic Investor in CAPTRUST

September 20, 2023

...

Abdul Latif Jameel Teams Up With AWS to Power Its Digital Transformation and Signs Renewable Energy Agreement With Amazon

September 20, 2023

...

Rockwell Automation and Infinitum Announce Agreement to Make High-Efficiency Low Voltage Drives and Motors Available for Energy-Intensive Industrial Applications

September 15, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NORTH AMERICAN BUSINESS All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NORTH AMERICAN BUSINESS All rights reserved.